OICC Press International Journal of Nano Dimension 2228-5059 17 3 2026 07 10 Engineering PVA-Based Nanofibrous Mats Containing Pramipexole with Anti-Parkinsonian Effects: Fabrication, Characterization, and Pharmacological Study 10.57647/ijnd.2026.1703.17 EN Maryam Ghaffarimoghadam Pharmaceutical Sciences Research Center, TeMS.C., Islamic Azad University, Tehran, Iran https://orcid.org/0000-0002-2956-9335 Mitra Baghali Research School of Chemistry & Applied Biomedical Sciences, Tomsk Polytechnic University, Lenin Avenue 43, 63400, Tomsk, Russian Federation Majid Motaghinejad Razi Drug Research Center, Iran University of Medical Sciences, Tehran, Iran https://orcid.org/0000-0003-3449-4224 Hakimeh Ziyadi Department of Organic Chemistry, TeMS.C., Islamic Azad University, Tehran, Iran Danial Sadri Pharmaceutical Sciences Research Center, TeMS.C., Islamic Azad University, Tehran, Iran Journal Article 2026 07 10 Parkinson’s disease is a progressive neurodegenerative disorder that requires long-term pharmacotherapy; however, conventional oral administration of pramipexole is associated with fluctuating plasma levels and systemic side effects. In this study, a novel electrospun PVA-based nanofibrous transdermal patch containing pramipexole was developed to enable controlled drug delivery and improved therapeutic efficacy. Pramipexole-loaded PVA and PVA/PVP nanofibers were fabricated via electrospinning and subsequently cross-linked using glutaraldehyde vapor. The nanofibrous mats were characterized in terms of morphology, wettability, rheological behavior, drug release kinetics, and in vivo neuroprotective performance. Smooth and bead-free nanofibers were obtained, confirming suitable solution viscosity and electrospinnability. Water contact angle measurements demonstrated hydrophilic behavior, with contact angles of 33° for PVA, 71° for PVA/PVP, and 43° for cross-linked PVA/PVP/pramipexole nanofibers, indicating tunable surface wettability. In vitro release studies revealed an initial burst release of approximately 43% and 32% of pramipexole within 30 min for PVA and PVA/PVP nanofibers, respectively, followed by sustained release reaching ~52% and ~49% after 24 h. In contrast, cross-linked nanofibers exhibited significantly slower and more controlled drug release due to reduced polymer network permeability. Histopathological analysis of the substantia nigra region in a paraquat-induced Parkinson’s disease model demonstrated a marked reduction in neuronal degeneration in both systemic and transdermal pramipexole-treated groups compared to untreated animals.